Literature DB >> 9053845

Suppression of the malignant phenotype of human glioma cells by overexpression of manganese superoxide dismutase.

W Zhong1, L W Oberley, T D Oberley, D K St Clair.   

Abstract

Manganese superoxide dismutase (MnSOD) has been previously shown to suppress the malignant phenotype of human melanoma and breast cancer cells. To test the possible role of MnSOD in glioma malignancy, MnSOD was overexpressed in wild type human glioma U118 cells and subcloned U118-9 cells by transfection of human MnSOD cDNA. The MnSOD-transfected cell lines demonstrated expression of exogenous (plasmid) MnSOD mRNA, increase in MnSOD immunoreactive protein, and a three- to eightfold increase in MnSOD enzymatic activity. The MnSOD overexpressing cell lines became less malignant as demonstrated by requiring a higher serum concentration to grow in vitro and much slower tumor growth in nude mice than the parental and neo control cell lines. These findings further support the hypothesis that MnSOD may be a tumor suppressor gene in a wide variety of human tumors.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9053845     DOI: 10.1038/sj.onc.1200852

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  53 in total

1.  Cloning, expression, and characterization of thermostable manganese superoxide dismutase from Thermoascus aurantiacus var. levisporus.

Authors:  Ning-Ning Song; Yan Zheng; Shi-Jin E; Duo-Chuan Li
Journal:  J Microbiol       Date:  2009-02-20       Impact factor: 3.422

2.  A TEAD1/p65 complex regulates the eutherian-conserved MnSOD intronic enhancer, eRNA transcription and the innate immune response.

Authors:  Ann L Chokas; Justin S Bickford; Sarah J Barilovits; Richard J Rogers; Xiaolei Qiu; Kimberly J Newsom; Dawn E Beachy; Harry S Nick
Journal:  Biochim Biophys Acta       Date:  2014-06-19

Review 3.  Anti-inflammatory/antioxidant use in long-term maintenance cancer therapy: a new therapeutic approach to disease progression and recurrence.

Authors:  Sarah Crawford
Journal:  Ther Adv Med Oncol       Date:  2014-03       Impact factor: 8.168

4.  Superior therapeutic index of calmangafodipir in comparison to mangafodipir as a chemotherapy adjunct.

Authors:  Jan Olof G Karlsson; Tino Kurz; Susanne Flechsig; Jacques Näsström; Rolf Gg Andersson
Journal:  Transl Oncol       Date:  2012-12-01       Impact factor: 4.243

5.  Identification of nucleophosmin as an NF-kappaB co-activator for the induction of the human SOD2 gene.

Authors:  Sanjit K Dhar; Bert C Lynn; Chotiros Daosukho; Daret K St Clair
Journal:  J Biol Chem       Date:  2004-04-15       Impact factor: 5.157

6.  Manganese superoxide dismutase induces p53-dependent senescence in colorectal cancer cells.

Authors:  Lars Behrend; Andrea Mohr; Tatjana Dick; Ralf M Zwacka
Journal:  Mol Cell Biol       Date:  2005-09       Impact factor: 4.272

7.  MnSOD Val16Ala polymorphism and prostate cancer susceptibility: a meta-analysis involving 8,962 subjects.

Authors:  Chen Mao; Li-Xin Qiu; Ping Zhan; Kai Xue; Hong Ding; Fang-Bing Du; Jin Li; Qing Chen
Journal:  J Cancer Res Clin Oncol       Date:  2009-12-10       Impact factor: 4.553

8.  CyclinB1/Cdk1 phosphorylates mitochondrial antioxidant MnSOD in cell adaptive response to radiation stress.

Authors:  Demet Candas; Ming Fan; Danupon Nantajit; Andrew T Vaughan; Jeffrey S Murley; Gayle E Woloschak; David J Grdina; Jian Jian Li
Journal:  J Mol Cell Biol       Date:  2012-12-12       Impact factor: 6.216

Review 9.  Molecular mechanisms of arsenic carcinogenesis.

Authors:  Chuanshu Huang; Qingdong Ke; Max Costa; Xianglin Shi
Journal:  Mol Cell Biochem       Date:  2004-01       Impact factor: 3.396

10.  Superoxide Enhances the Antitumor Combination of AdMnSOD Plus BCNU in Breast Cancer.

Authors:  Wenqing G Sun; Christine J Weydert; Yuping Zhang; Lei Yu; Jingru Liu; Douglas R Spitz; Joseph J Cullen; Larry W Oberley
Journal:  Cancers (Basel)       Date:  2010-02-12       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.